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Sir,
Dr Herbert makes a number of points about our paper that we
shall address in turn. Her basic thesis is that when coverage is
high, comparison of cervical smear histories in women with and
without cancer does not provide useful estimates of the effective-
ness (or even the relative effectiveness) of screening at different
ages. We strongly disagree. Although observational studies are
subject to bias, we do not believe that this can explain the
substantial differences in effectiveness that we observed across
different age groups. The percentage of women with a screening
smear is almost identical in cases and controls aged 20–29 years
(74.3 vs 74.8%), underlying the lack of effectiveness of screening in
this group compared to women aged 45–64 years, in whom
coverage is much greater among controls (81.5 vs 59.0%).
We agree that some of the screening in our study dates back to
the late 1980s and that a variety of quality assurance measures have
been introduced since. However, in general, one would expect any
advantage of 3-yearly screening over 5-yearly screening to
diminish as the quality of screening improves. Table 1b provides
an analysis restricted to cases (and their controls) diagnosed since
January 1995. The results are quantitatively similar (and qualita-
tively unchanged) to those presented in our paper (Table 1a).
Although it is true that screening coverage improved consider-
ably between 1987 and 1993, the claim that, in 1994–1995, over
90% of women had been screened is erroneous. This figure is
based on the proportion who had been (or were due to be) sent an
invitation, not the proportion actually screened. No data exist for
the proportion of women aged 25–64 years in 1994 who had ever
been screened. However, it is unlikely to be that much greater than
the proportion screened in the previous 5 years (85.7%), since
coverage was low prior to 1990 and women screened then were
likely to return for screening when invited. Additionally, the
relevance of this to comparing 3- vs 5-yearly screening is dubious.
We do not believe that cases with unknown stage were
more likely to be fully invasive. Most Health Authorities
provided information on stage from all or none of the cases for
a given year. Restricting analysis to sources that provided complete
staging on all cases submitted made little difference to the results
(Table 1c).
We agree that due to the poor sensitivity of cervical cytology, the
number of previous recent smears is also important. This was
illustrated in Tables 3 and 4, in which the added affect of having
more than one previous smear was estimated. The results further
support our main finding that screening is less effective in younger
women. The additional relative benefit of a second negative smear
in women aged 20–39 years was only 1.03 compared to 1.32 and
1.35 for women aged 40–54 and 55–69 years, respectively.
Dr Herbert points out that in 1998 over 4000 cases of CIN3 were
detected in UK women under 25 years. What she does not say is
that this compares with fewer than 50 cases of invasive cancer
under age 25 years (compared to 440 aged 35–39 years). Given that
screening has so little effect on incidence in this age group and the
fact that the age-specific rate is not much greater anywhere in the
world, we doubt that the number would have been appreciably
larger in the absence of screening. Furthermore, the extremely
small number of cancers prevented (if any) by screening under the
age of 25 years must be balanced against the extremely high rates
of cytological abnormality (15%) and unnecessary treatment, with
a complication rate of cervical stenosis in up to 3% of those treated
(Luesley et al, 1985).
There is no point in detecting precancer if this does not prevent
invasive cancer. Cervical screening does detect very large numbers
of CIN3 in young women, but the evidence is that it does little to
prevent cancer. The reason must be that the vast majority of CIN3
in young women will not progress to cancer. Surely, it is better to
start screening at the age of 25 years when many of the CIN lesions
(including CIN3) will have regressed, but extremely few will have
progressed to cancer; especially as there is no evidence that
screening can prevent the rare but rapidly progressing lesions
from becoming cancer.
Down-staging invasive cancers is indeed a useful effect of
screening. However, an increase in microinvasive cancers that is
not accompanied by a decrease in fully invasive cancer must be
questioned. Our study shows that there is little or no reduction in
fully invasive cervical cancer in women in their twenties associated
with screening.
We remain confident of our findings and feel that the
government is justified in changing their policy to only invite
women for screening from age 25 years in England. No one would
introduce a screening programme for a disease that effects fewer
than 15 in 100000 women (the cumulative rate of cervical cancer
up to age 25 years, which has changed little since 1988),
particularly when there is little evidence of its effectiveness and
substantial evidence of harm.
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Table 1 Odds ratios for fully invasive cervical cancer by time since last operationally negative cytological smear
Odds ratio (95% CI)
Age 20–39 (n¼438) 40–54 (n¼481) 55–69 (n¼386)
(a) All data
No previous negative 1.0* 1.0* 1.0*
Time since last negative smear
0–2.9 0.28 (0.20–0.41) 0.12 (0.08–0.17) 0.13 (0.08–0.19)
3.0–4.9 1.03 (0.68–1.56) 0.39 (0.26–0.58) 0.20 (0.12–0.33)
Over 5.0 2.05 (1.20–3.49) 0.72 (0.43–1.18) 0.45 (0.25–0.81)
Age 20–39 (n¼183) 40–54 (n¼229) 55–69 (n¼160)
(b) Women diagnosed since 1995
No previous negative 1.0* 1.0* 1.0*
Time since last negative smear
0–2.9 0.28 (0.16–0.51) 0.08 (0.05–0.15) 0.11 (0.06–0.20)
3.0–4.9 1.34 (0.70–2.57) 0.34 (0.18–0.62) 0.19 (0.09–0.42)
Over 5.0 2.80 (1.26–6.22) 0.65 (0.31–1.36) 0.35 (0.15–0.79)
Age 20–39 (n¼221) 40–54 (n¼260) 55–69 (n¼225)
(c) Data restricted to Health Authorities with staging information for all women
No previous negative 1.0* 1.0* 1.0*
Time since last negative smear
0–2.9 0.32 (0.19–0.53) 0.09 (0.05–0.16) 0.10 (0.06–0.18)
3.0–4.9 0.96 (0.52–1.74) 0.34 (0.19–0.59) 0.18 (0.10–0.34)
Over 5.0 1.81 (0.88–3.75) 0.78 (0.38–1.60) 0.33 (0.16–0.69)
*Reference group.
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